Goldis Malek PhD

Dr. Malek is focused on investigating the cellular and molecular pathogenic mechanisms underlying the three clinical subtypes of AMD. She was driven by a desire to further understand signaling pathways critical in the initiation and progression of AMD and hopefully identify therapeutic targets for this debilitating degenerative disease. Two major lines of investigation currently being followed concomitantly include (1) elucidating the role of lipid-mediated injury of retinal pigment epithelial cells and how this injury promotes pathogenic changes in Bruch’s membrane and drusen formation, key features of the dry AMD subtype, through activation of the nuclear receptors peroxisome proliferator-activated receptors and liver-X receptors and (2) investigating the role of the xenobiotic responsive aryl hydrocarbon receptor in regulating cellular metabolism in two other subtypes of AMD, geographic atrophy and neovascular AMD.